Dr. Bart Tarbet received his Ph.D. in Animal Science from the University of Delaware, with specialization in pathology (experimental). His M.S. degree in Microbiology and Immunology was completed at the Louisiana State University Medical Center, and his undergraduate work in Microbiology was done at Weber State University. He joined the Institute for Antiviral Research at Utah State University in 2008. Prior to joining USU, Dr. Tarbet was employed in Research and Development at Intervet Inc. (now Merck Animal Health), a global leader in the discovery, development, and manufacture of veterinary medicines. During the twelve years that he worked at Intervet he completed proprietary research in the area of vaccine development.
His current research includes:
- In vitro evaluation of antivirals against influenza virus,
- Animal models of influenza virus infection, and
- Evaluation of experimental therapies and vaccines against influenza virus.
Dr. Tarbet also teaches Ethical Issues in Genetic Engineering and Biotechnology (ADVS 3200) in the Department of Animal, Dairy and Veterinary Science, and is a faculty member in the USU School of Veterinary Medicine, where he teaches Veterinary Bacteriology and Mycology (VM 7536) and a practicum in Leadership (VM 7596).
In addition, Dr. Tarbet is on the Editorial Boards of Antiviral Chemistry & Chemotherapy, Journal of Virology & Antiviral Research, and Therapeutic Advances in Vaccines.